Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs to reduce scarring, improve wound healing and enhance tissue regeneration, announces that at its Annual General Meeting (AGM) held today all resolutions were duly passed.
Details of the proxies received in respect of each resolution may be viewed via the download in related items to the right.
Printer-friendly version